Kelly Frye

Title: Kelly Frye: Innovating in VEGF Antagonist Formulations

Introduction

Kelly Frye, an accomplished inventor based in Mendham, NJ, has made significant contributions to the field of biopharmaceuticals. With a remarkable portfolio of 23 patents, he is known for his work on vascular endothelial growth factor (VEGF) antagonist formulations. His inventions have the potential to advance treatment protocols in ocular therapies and more.

Latest Patents

Among Frye's latest patents is a collection focused on citrate buffered VEGF antagonist formulations. These formulations include a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation, with an emphasis on a fusion protein featuring the sequence of SEQ ID NO:4. Additionally, he has developed ophthalmic formulations suitable for intravitreal administration, which also incorporate a VEGF-specific fusion protein antagonist and provide stable liquid and lyophilizable options.

Career Highlights

Kelly Frye is currently employed at Regeneron Pharmaceuticals, Inc., a leading biopharmaceutical company committed to advancing innovative treatments. His work is pivotal in developing therapies that could greatly benefit patients suffering from eye conditions caused by abnormal vascular growth.

Collaborations

Frye collaborates with esteemed colleagues in his field, including Daniel B Dix and Eric Steven Furfine. Together, they contribute to the innovative spirit of Regeneron and push the boundaries of biopharmaceutical research.

Conclusion

Through his inventive contributions, Kelly Frye continues to make an important impact in the realm of biopharmaceuticals. His extensive patent portfolio highlights his commitment to developing groundbreaking therapies that address critical medical needs, particularly in the area of ophthalmology. As the industry evolves, Frye’s innovations will undoubtedly play a crucial role in shaping future treatment options.